Reviewing Alnylam Pharmaceuticals (ALNY) & Jaguar Animal Health (JAGX)
Alnylam Pharmaceuticals (NASDAQ: ALNY) and Jaguar Animal Health (NASDAQ:JAGX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.
Valuation and Earnings
This table compares Alnylam Pharmaceuticals and Jaguar Animal Health’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Alnylam Pharmaceuticals||$66.00 million||172.62||-$436.51 million||($5.12)||-24.26|
|Jaguar Animal Health||$1.79 million||11.85||-$111.45 million||($1.03)||-0.19|
Jaguar Animal Health has higher revenue, but lower earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
This table compares Alnylam Pharmaceuticals and Jaguar Animal Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jaguar Animal Health||-757.17%||N/A||-301.91%|
Insider and Institutional Ownership
94.3% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Jaguar Animal Health shares are held by institutional investors. 4.3% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 19.5% of Jaguar Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for Alnylam Pharmaceuticals and Jaguar Animal Health, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jaguar Animal Health||0||0||2||0||3.00|
Alnylam Pharmaceuticals presently has a consensus target price of $105.42, indicating a potential downside of 15.12%. Jaguar Animal Health has a consensus target price of $2.00, indicating a potential upside of 920.41%. Given Jaguar Animal Health’s stronger consensus rating and higher probable upside, analysts clearly believe Jaguar Animal Health is more favorable than Alnylam Pharmaceuticals.
Volatility & Risk
Alnylam Pharmaceuticals has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.
Alnylam Pharmaceuticals beats Jaguar Animal Health on 7 of the 13 factors compared between the two stocks.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company’s lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
Jaguar Animal Health Company Profile
Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.